Recently, the U.S.’s changed position on IP Waiver for patent protection of the COVID-19 vaccines and technology grabbed the headlines. It was an about-face from its previous stance. But what does it all mean?
From Facebook...more
Neal Gerber Eisenberg and Wolters Kluwer have teamed up to bring you NGE IP Focus, a quarterly newsletter dedicated to intellectual property-related legal decisions.
...more
1/24/2019
/ Gilead Sciences ,
Intellectual Property Protection ,
Inventions ,
Life Sciences ,
Obviousness ,
Opioid ,
Pain Management ,
Patent Infringement ,
Patent Invalidity ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Section 101